A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder

Completed · Phase 2

Conditions studied: Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder

In brief

This is a Phase IIa study to evaluate the efficacy, safety and tolerability of GW679769 vs placebo on symptoms of urgency with urge incontinence, frequency and nocturia associated with overactive bladder in women.

Key facts

Study ID

NCT00321477

Run by

GlaxoSmithKline

People needed

160

Starts

2005-12-01

Expected to finish

2007-02-01

Last updated by the study team

2017-01-20

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female subjects with overactive bladder with symptoms of urgency with urge incontinence and frequency which may be associated with nocturia but without bladder pain.
• Must not be pregnant.
• Must not be of childbearing potential or is willing to use specific barrier methods outlined in the protocol.
• Body weight in the range of = 45 kg and <100 kg.

You may not qualify if…

• Stage III/IV pelvic organ prolapse with or without cystocele.
• History of interstitial cystitis or bladder related pain.
• Subjects with stress incontinence or mixed incontinence where stress incontinence is the predominant component based on prior history.
• History of pelvic prolapse repair (cystocele or rectocele) or urethral diverticulectomy within six months of screening.
• Subjects with urinary incontinence due to causes other then detrusor over activity (e.g., overflow incontinence).
• Nocturnal enuresis only.
• Urinary retention, or other evidence of poor detrusor function.
• History of prior anti-incontinence surgery.
• History of radiation cystitis or a history of pelvic irradiation.
• Electrostimulation, biofeedback, or bladder training therapy (behavioral therapy) during the previous month prior to screening, or the intention to initiate such therapies during the study. Pessaries and implants are also excluded.
• Participated in any clinical trial of an investigation drug that may affect urinary function within 3 months of enrollment into the study.
• Received any investigational product within 30 days of enrollment into the study.

Where it is running

• GSK Investigational Site — Peoria, Arizona, United States
• GSK Investigational Site — Phoenix, Arizona, United States
• GSK Investigational Site — La Mesa, California, United States
• GSK Investigational Site — Modesto, California, United States
• GSK Investigational Site — San Bernardino, California, United States
• GSK Investigational Site — Torrance, California, United States
• GSK Investigational Site — Aurora, Colorado, United States
• GSK Investigational Site — Denver, Colorado, United States
• GSK Investigational Site — Denver, Colorado, United States
• GSK Investigational Site — Longmont, Colorado, United States
• GSK Investigational Site — Waterbury, Connecticut, United States
• GSK Investigational Site — Aventura, Florida, United States
• GSK Investigational Site — Clearwater, Florida, United States
• GSK Investigational Site — Fort Myers, Florida, United States
• GSK Investigational Site — Miami, Florida, United States
• GSK Investigational Site — Miami, Florida, United States
• GSK Investigational Site — Ocala, Florida, United States
• GSK Investigational Site — Pembroke Pines, Florida, United States
• GSK Investigational Site — Sarasota, Florida, United States
• GSK Investigational Site — Atlanta, Georgia, United States
• GSK Investigational Site — Melrose Park, Illinois, United States
• GSK Investigational Site — Indianapolis, Indiana, United States
• GSK Investigational Site — Jeffersonville, Indiana, United States
• GSK Investigational Site — Newburgh, Indiana, United States
• GSK Investigational Site — Huntsville, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.